Structure and Function of the Adrenergic Receptor Family

  • Neil S. Roth
  • Robert J. Lefkowitz
  • Marc G. Caron
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 308)


The interaction of hormones and drugs with their respective targets has been widely studied with the hope that a better understanding of the molecular basis of their actions would provide insights not only into the nature of their specific mechanisms but those involved in certain pathophysiologic states. Receptors represent the central locus of interaction between ligands/drugs and cells. Adrenergic receptors because of their ubiquitous and well defined effector mechanisms have been excellent models for the study of these processes. Catecholamines and various synthetic analogs bind to adrenergic receptors that are integral membrane proteins and lead to the generation of intracellular second messengers culminating in a physiologic response. As with many other types of receptors this cascade of events is mediated by specific effector molecules which are coupled to adrenergic receptors in the plasma membrane. These intermediary signal transducing proteins are called guanine nucleotide regulatory proteins or G-proteins because they bind and hydrolyze guanine nucleotide triphosphate (1).


Adenylyl Cyclase Cytoplasmic Loop Homologous Desensitization Rhodopsin Kinase Seventh Transmembrane Domain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gilman AG. G-Proteins: Transducers of receptors generated signals. Ann Rev Biochem 56: 615, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Lefkowitz RJ, and Caron MG. Adrenergic Receptors: Models for the study of receptors coupled to guanine nucleotide regulatory proteins. J Biol Chem 263: 4993, 1988.PubMedGoogle Scholar
  3. 3.
    Emorine LJ, Marullo S, Briend-Sutren M-M, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD. Molecular characterization of the human β3-adrenergic receptor. Science 245: 1118, 1989.PubMedCrossRefGoogle Scholar
  4. 4.
    Bylund DB. Subtypes of α2-adrenoceptor: Pharmacological and molecular biological evidence coverge. Trends Pharmacol Sci 9: 356, 1988.PubMedCrossRefGoogle Scholar
  5. 5.
    McGrath J, Wilson V. α-Adrenoceptor subclassification by classical and response-related methods: Same questions, different answers. Trends Pharmacol Sci 9: 162, 1988.PubMedCrossRefGoogle Scholar
  6. 6.
    Schwinn DA, Lomasney JW, Lorenz W, Szklut P, Fremeau RT, Jr, Yang-Feng TL, Caron MG, Lefkowitz RJ, and Cotecchia S. Molecular cloning and expression of the cDNA for a novel al-adrenergic receptor subtype J Biol Chem 265: 8183, 1990.PubMedGoogle Scholar
  7. 7.
    Lomasney JW, Lorenz W, Allen LF, King K, Regan JW, Yang-Feng TL, Caron MG, and Lefkowitz RJ. Expansion of the α2-adrenergic receptor family: cloning and characterization of a human α2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci (USA) 87: 5094, 1990.CrossRefGoogle Scholar
  8. 8.
    Sibley DR, Benovic JL, Caron MG, and Lefkowitz RJ. Regulation of transmembrane signalling by receptor phosphorylation. Cell 48: 913, 1987.PubMedCrossRefGoogle Scholar
  9. 9.
    Berridge MJ, and Irvine R. Inositol triphosphate: A novel second messenger in cellular signal transduction. Nature 312: 315, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    Yatani A, Codina J, Brown AM, and Birnbaumer L. Direct activation of mammalian atrial muscarinic K channels by a human erythrocyte pertussis toxin-sensitive G protein, Gk. Science 235: 207, 1987.CrossRefGoogle Scholar
  11. 11.
    Yatani A, Codina J, Imoto Y, Reeves JP, Birnbaumer L, and Brown AM. A G protein directly regulates mammalian cardiac calcium channels. Science 238: 1288, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    Cotecchia S, Kobilka B, Daniel K, Nolan RD, Lapetina EY, Caron MG, and Lefkowitz RJ. Multiple second messenger pathways of aadrenergic receptor subtypes expressed in eukaryotic cells,. J Biol Chem 265: 63, 1990.PubMedGoogle Scholar
  13. 13.
    Peralta EG, Ashkenazi A, Winslow JW, Ramachandran J, and Capon DJ. Differential regulation of phosphatidyl inositol hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature 334: 434, 1988.PubMedCrossRefGoogle Scholar
  14. 14.
    Fargin A, Raymond JR, Regan JW, Cotecchia S, Lefkowitz RJ, and Caron MG. Effector coupling mechanisms of the 5-HT1A receptor, J Biol Chem 264: 14848, 1989.PubMedGoogle Scholar
  15. 15.
    Nathans J, Thomas D, and Hogness DS. Molecular genetics of human color vision: The genes encoding blue, green, and red pigments. Science 232: 193, 1986.PubMedCrossRefGoogle Scholar
  16. 16.
    Jones DT, and Reed RR. Golf: An olfactory neuron specific-G protein involved in odorant signal transduction. Science 244: 790, 1989.PubMedCrossRefGoogle Scholar
  17. 17.
    Lefkowitz RJ, and Caron MG. Molecular and regulatory properties of adrenergic receptors. Recent Prog Horm Res 43: 469, 1987.PubMedGoogle Scholar
  18. 18.
    Henderson R, and Unwin PNT. Three dimensional model of purple membrane obtained by electon microscopy. Nature 257: 28, 1975.PubMedCrossRefGoogle Scholar
  19. 19.
    Dohlman HG, Bouvier M, Benovic JL, Caron MG, and Lefkowitz RJ. The multiple membrane spanning topography of the β2-adrenergic receptor. Localization of the sites of binding, glycosylation and regulatory phosphorylation by limited proteolysis. J Biol Chem 262: 14282, 1987.PubMedGoogle Scholar
  20. 20.
    Wang H, Lipfert L, Malbon CC, and Bahouth S. Site-directed anti-peptide antibodies define the topography of the beta-adrenergic receptor. J Biol Chem 264: 14424, 1989.PubMedGoogle Scholar
  21. 21.
    Dixon RAF, Sigal IS, Candelore MR, Register RB, Scattergood W, Rands E, and Strader CD. Structural features required for ligand binding to the β-adrenergic receptor. EMBO J 6: 3269, 1987.PubMedGoogle Scholar
  22. 22.
    Rands E, Candelore MR, Cheung AH, Hill WS, Strader CD, and Dixon RAF. Mutational analysis of β-adrenergic receptor glycosylation. J Biol Chem 265: 10759, 1990.PubMedGoogle Scholar
  23. 23.
    Fraser CM. Site-directed mutagenesis of β-adrenergic receptors. Identification of conserved cysteine residues that independently affect ligand binding and receptor activation. J Biol Chem 264: 9266, 1989.PubMedGoogle Scholar
  24. 24.
    Dohlman HG, Caron MG, DeBlasi A, Frielle T, and Lefkowitz RJ. A role of extracellular disulfide bonded cysteines in the ligand binding function of the β2-adrenergic receptor. Biochemistry 29: 2335, 1990.PubMedCrossRefGoogle Scholar
  25. 25.
    Karnik SS, Sakmar TP, Chen H-B, and Khorana HG. Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. Proc Natl Acad Sci (USA) 85: 8459, 1988.CrossRefGoogle Scholar
  26. 26.
    Dohlman HG, Caron MG, Strader CD, Amlaik N, and Lefkowitz RJ. Identification and sequence of a binding site peptide of the β2-adrenergic receptor. Biochem 27: 1813, 1988.CrossRefGoogle Scholar
  27. 27.
    Matsu H, Lefkowitz RI, Caron MG, and Regan JW. Localization of the fourth membrane spanning domain as a ligand binding site in the human platelet α2-adrenergic receptor. Biochem 28: 4125, 1989.CrossRefGoogle Scholar
  28. 28.
    Cirtis CAM, Wheatley M, Bansal S, Birdsall NJM, Eveleight P, Pedder EK, Poyner D, and Hulme EC. Propylbenzilcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. J Biol Chem 264: 89, 1989.Google Scholar
  29. 29.
    Wong SK-F, Slaughter C, Ruoho AE, and Ross EM. The catecholamine binding site of the β-adrenergic receptor is formed by juxtaposed membrane-spanning domains J Biol Chem 263: 7925, 1988.PubMedGoogle Scholar
  30. 30.
    Barclay DC, and Findlay JBC. Labeling of the cytoplasmic domains of ovine rhodopsin with hydrophilic photoaffinity probes. Biochem J 220: 75, 1984.PubMedGoogle Scholar
  31. 31.
    Thomas DD, and Stryer L. Transverse location of the retinal chromophore of rhodopsin in rod outer segment disc membranes. J Mol Biol 154: 145, 1982.PubMedCrossRefGoogle Scholar
  32. 32.
    Dixon RAF, Sigal IS, Rands E, Register RB, Candelore MR, Blake AD, and Strader CD. Ligand binding to β-adrenergic receptor involves its rhodopsin-like core. Nature 326: 73, 1987.PubMedCrossRefGoogle Scholar
  33. 33.
    Kobilka BK, MacGregor C, Daniel K, Kobilka TS, Caron MG, and Lefkowitz RJ. Functional activity and regulation of human β2-adrenergic receptors expressed in xenopus oocytes. J Biol Chem 262: 7321, 1987.PubMedGoogle Scholar
  34. 34.
    Strader CD, Sigal IS, Candelore MR, Rands E, and Dixon RAF. Identification of residues required for ligand binding to the β-adrenergic receptor. Proc Natl Acad Sci (USA) 84: 4384, 1987.CrossRefGoogle Scholar
  35. 35.
    Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, and Dixon RAF. Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J Biol Chem 263: 4052, 1988.Google Scholar
  36. 36.
    Chung F-Z, Wang C-D Potter PC, Venter JC, and Fraser CM. Site-directed mutagenesis and continuous expression of human β-adrenergic receptors. J Biol Chem 263: 4052, 1988.PubMedGoogle Scholar
  37. 37.
    Frielle T, Daniel K, Caron MG, and Lefkowitz RJ. Structural basis of β-adrenergic receptor subtype specificity studied with chimeric β1, β2-adrenergic receptors. Proc Natl Acad Sc (USA) 85: 9494, 1988.CrossRefGoogle Scholar
  38. 38.
    Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, and Lefkowitz RJ. Chimeric α22-adrenergic receptors: Delineation of domains involved in effector coupling and ligand binding specificity. Science 240: 1310, 1988.PubMedCrossRefGoogle Scholar
  39. 39.
    Strader CD, Candelore MR, Hill WS, Sigal IS, and Dixon RAF. Identification of two serine residues involved in agonist activation of the ßadrenergic receptor. J Biol Chem 264: 13572, 1989.PubMedGoogle Scholar
  40. 40.
    Strader CD, Sigal IS, and Dixon RAF. Structural basis of ßadrenergic receptor function. FASEB J 3: 1825, 1989.PubMedGoogle Scholar
  41. 41.
    O’Dowd BF, Hnatowich M, Regan JW, Leader W.M, Caron MG, and Lefkowitz RJ. Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor. J Biol Chem 263: 15985, 1988.PubMedGoogle Scholar
  42. 42.
    O’Dowd BF, Hnatowich M, Caron, MG, Lefkowitz RJ, Bouvier M. Palmitoylation of the human β2-adrenergic receptor. J Biol Chem 264: 7564, 1989.PubMedGoogle Scholar
  43. 43.
    Ovchinnikov YA, Adulaev NG, and Bogachuk AS. Two adjacent cysteine residues in the C-terminal cytoplasmic fragment of bovine rhodopsin are palmitylated. FEBS Lett 230: 1, 1988.PubMedCrossRefGoogle Scholar
  44. 44.
    Stiles GL. Drug and hormonal regulation of the β-adrenergic receptor–adenylate cyclase systems. In The β-Adrenergic Receptor (Perkins, J.P., Ed) Humana Press, New York, pp. 345–386, 1991.CrossRefGoogle Scholar
  45. 45.
    Perkins JP, Hausdorff WP, and Lefkowitz RJ. Mechanisms of ligand-induced desensitization of β-adrenergic receptors. In The β-Adrenergic Receptor (Perkins, J.P., Ed) Humana Press, New York, pp. 73179, 1991.CrossRefGoogle Scholar
  46. 46.
    Hausdorff WP, Caron MG, and Lefkowitz RJ. Turning off the signal: desensitization of the β-adrenergic receptor function. FASEB J 4: 2881, 1990.PubMedGoogle Scholar
  47. 47.
    Sibley DR, Benovic JL, Caron MG, and Lefkowitz. J. Regulation of transmembrane signaling by receptor phosphorylation Cell 48: 913, 1987.PubMedCrossRefGoogle Scholar
  48. 48.
    Benovic JL, Pike LJ, Cerion RA, Staniszewski C, Yoshimasa T, Codina J, Caron MG, and Lefkowitz RJ. Phosphorylation of the mammalian β-adrenergic receptor by cyclic AMP-dependent kinase. J Biol Chem 260: 7094, 1985.PubMedGoogle Scholar
  49. 49.
    Bouvier M, Leeb-Lundberg LMF, Benovic JL, Caron MG, and Lefkowitz RJ. Regulation of adrenergic receptor function by phosphorylation. J Biol Chem 262: 3106, 1987.PubMedGoogle Scholar
  50. 50.
    Benovic JL, Strasser RH, Caron MG, and Lefkowitz RJ. β-Adrenergic receptor kinase: Identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci (USA) 83: 2797, 1986.CrossRefGoogle Scholar
  51. 51.
    Benovic JL, Mayor F, Jr, Staniszewski C. Lefkowitz RJ, and Caron MG. Purification and characterization of the β-adrenergic receptor kinase. J Biol Chem 262: 9026, 1987.PubMedGoogle Scholar
  52. 52.
    Benovic JL, DeBlasi A, Stone WC, Caron MG, and Lefkowitz RJ. β-Adrenergic receptor kinase: Primary structure delineates a multigene family. Science 246: 2 35, 1989.CrossRefGoogle Scholar
  53. 53.
    Benovic JL, Kuhn H, Weyand I, Codina J, Caron MG, and Lefkowitz RJ. Functional desensitization of the isolated β-adrenergic receptor by the β-adrenergic receptor kinase: Potential role of an analog of the retinal binding protein arrestin (48-kDa). Proc Natl Acad Sci (USA) 84: 8879, 1987.CrossRefGoogle Scholar
  54. 54.
    Wilden U, Hall SW, and Ku Ohn H. Phosphodiesterase activation by photoexited rhodopsin is quenched when rhodopsin is phosphorylated and binds to the intrinsic 48-kDa protein of the rod outer segment. Proc Natl Acad Sci (USA) 83: 1174, 1986.CrossRefGoogle Scholar
  55. 55.
    Shinohara T, Dietzschold B, Craft CM, Wistow G, Early JJ, Donoso LA, Horowitz J, and Tao R. Primary and secondary structure of bovine retinal S-antigen (48-kDa protein). Proc Natl Acad Sci (USA) 84: 6975, 1987.CrossRefGoogle Scholar
  56. 56.
    Lohse MJ, Benovic JL, Codina J, Caron MG, and Lefkowitz RJ. OArrestin: A protein that regulates β-adrenergic receptor function. Science 248: 1547, 1990.PubMedCrossRefGoogle Scholar
  57. 57.
    Benovic JL, Mayor F, Jr, Somers RL, Caron MG, and Lefkowitz RJ. Light-dependent phosphorylation of rhodopsin by β-adrenergic receptor kinase. Nature 322: 867, 1986.Google Scholar
  58. 58.
    Hausdorff WP, Bouvier M, O’Dowd BF, Irons GP, Caron MG, and Lefkowitz RJ. Phosphorylation sites on two domains of the β2-adrenergic receptor are involved in distinct pathways of receptor desensitization. J Biol Chem 264: 1 2657, 1989.Google Scholar
  59. 59.
    Lohse MJ, Lefkowitz RJ, Caron MG, and Benovic JL. Inhibition of 0adrenergic receptor kinase prevents rapid homologous desensitization of β2-adrenergic receptors. Proc Natl Acad Sci (USA) 86: 3011, 1989.CrossRefGoogle Scholar
  60. 60.
    Lohse MJ, Benovic JL, Caron MG, and Lefkowitz RJ. Multiple pathways of rapid β2-adrenergic receptor desensitization: Delineation with specific inhibitors. J Biol Chem 265: 3202, 1990.PubMedGoogle Scholar
  61. 61.
    Cheung AH, Sigal IS, Dixon RAF.,and Strader CA. Agonistpromoted sequestration of the β2-adrenergic receptor requires regions involved in functional coupling with Gs. Mol Pharmacol 34: 132, 1989.Google Scholar
  62. 62.
    Campbell PT, Hnatowich M, O’Dowd BF, Caron MG, Lefkowitz RJ. and Hausdorff, W.P., Mutations of the human β2-adrenergic receptor that impair coupling to GS interfere with receptor down-regulation but not sequestration. Mol Pharmacol 39: 192, 1991.PubMedGoogle Scholar
  63. 63.
    Boúvier M, Collins S, Caron MG, and Lefkowitz RJ. Two distinct pathways for cAMP mediated down regulation of the β2-adrenergic receptor: Phosphorylation of the receptor and regulation of its mRNA level. J Biol Chem 264: 16786, 1989.PubMedGoogle Scholar
  64. 64.
    Collins S, Bouvier M, Bolanowski MA, Caron MG, and Lefkowitz RJ. cAMP stimulates transcription of β2-adrenergic receptor gene in response to short-term agonist exposure. Proc Natl Acad Sci (USA) 86: 4853, 1989.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Neil S. Roth
    • 1
  • Robert J. Lefkowitz
    • 1
  • Marc G. Caron
    • 1
  1. 1.Howard Hughes Medical Institute Departments of Cell Biology, Medicine, and BiochemistryDuke University Medical CenterDurhamUSA

Personalised recommendations